Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Hedner

Showing results (211-220 of 242) with videos related to

Pageof 25
Sort By:
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 1, 1995
Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia AE Erhardtsen, M Ezban, M T Madsen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 1, 2010
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsH Agersø, D F Brophy, H Pelzer, et al.
Journal of Thrombosis and Haemostasis : JTH|March 1, 2012
Influence of endothelial cell protein C receptor on plasma clearance of factor VIIaR Gopalakrishnan, U R Pendurthi, U Hedner, et al.
Thrombosis Research|September 15, 1989
Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-NovoA Siegbahn, S Y-Hassan, J Boberg, et al.
Thrombosis and Haemostasis|April 1, 1996
Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparinJ Holst, B Lindblad, S E Matthíasson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 13, 2009
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech RepublicP Salaj, P Brabec, M Penka, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1985
Polymorphism of normal factor IX detected by mouse monoclonal antibodiesA Wallmark, R Ljung, I M Nilsson, et al.
European Journal of Clinical Pharmacology|January 1, 1984
Actions and interactions of acetylsalicylic acid, salicylic acid and diflunisal on platelet aggregationE Nitelius, B Brantmark, B Fredholm, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 31, 1997
Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human bloodU Orvim, R M Barstad, L Orning, et al.
Thrombosis and Haemostasis|September 1, 1993
Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbitsC Bregengaard, O Nordfang, P Ostergaard, et al.
Pageof 25

Showing results (211-220 of 242) with videos related to

Sort By:
Pageof 25
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|July 1, 1995
Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia AE Erhardtsen, M Ezban, M T Madsen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 1, 2010
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsH Agersø, D F Brophy, H Pelzer, et al.
Journal of Thrombosis and Haemostasis : JTH|March 1, 2012
Influence of endothelial cell protein C receptor on plasma clearance of factor VIIaR Gopalakrishnan, U R Pendurthi, U Hedner, et al.
Thrombosis Research|September 15, 1989
Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-NovoA Siegbahn, S Y-Hassan, J Boberg, et al.
Thrombosis and Haemostasis|April 1, 1996
Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparinJ Holst, B Lindblad, S E Matthíasson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 13, 2009
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech RepublicP Salaj, P Brabec, M Penka, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1985
Polymorphism of normal factor IX detected by mouse monoclonal antibodiesA Wallmark, R Ljung, I M Nilsson, et al.
European Journal of Clinical Pharmacology|January 1, 1984
Actions and interactions of acetylsalicylic acid, salicylic acid and diflunisal on platelet aggregationE Nitelius, B Brantmark, B Fredholm, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 31, 1997
Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human bloodU Orvim, R M Barstad, L Orning, et al.
Thrombosis and Haemostasis|September 1, 1993
Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbitsC Bregengaard, O Nordfang, P Ostergaard, et al.
Pageof 25